A modified, long-acting analog of insulin-like growth factor 1 widely used as a research reagent in cell-culture and preclinical growth studies.
Mechanism under study
Activates the IGF-1 receptor to promote cell growth and proliferation; the Long R3 modifications reduce binding to IGF-binding proteins, substantially extending its active half-life versus native IGF-1.
Research-reported dosing
As a research reagent, references vary widely (commonly ~20–50 mcg ranges in animal work). Not established or appropriate as a human therapeutic.
Based on a standard 1 mg vial: with 2 mL bacteriostatic water = 500 mcg/mL (0.5 mg/mL); 1 unit ≈ 5 mcg.
A 40 mcg dose ≈ 8 units (5 mcg per unit).
Open this mix in the calculator →Source research-grade IGF-1 LR3 ↗Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
IGF-1 LR3 FAQ
What is IGF-1 LR3?
A modified, long-acting analog of insulin-like growth factor 1 widely used as a research reagent in cell-culture and preclinical growth studies.
What is the half-life of IGF-1 LR3?
Extended versus native IGF-1 — research references on the order of 20–30 hours.
What is the research-reported dosing for IGF-1 LR3?
As a research reagent, references vary widely (commonly ~20–50 mcg ranges in animal work). Not established or appropriate as a human therapeutic.
How is IGF-1 LR3 reconstituted?
Based on a standard 1 mg vial: with 2 mL bacteriostatic water = 500 mcg/mL (0.5 mg/mL); 1 unit ≈ 5 mcg.
Is IGF-1 LR3 FDA-approved?
No — IGF-1 LR3 is not FDA-approved and is sold for laboratory research use only.
References
Guides featuring IGF-1 LR3
Related peptides
BPC-157
Synthetic pentadecapeptide
A stable synthetic peptide based on a partial sequence identified in gastric juice. It is one of the most-studied research peptides for connective-tissue and gut-lining repair in animal models.
TB-500
Synthetic actin-binding peptide fragment
A synthetic fragment related to Thymosin Beta-4, a naturally occurring actin-regulating peptide. Studied in preclinical models for cell migration, wound healing, and flexibility.
CJC-1295
Growth-hormone-releasing hormone (GHRH) analog
A synthetic GHRH analog studied for stimulating growth-hormone release. Exists in a short-acting 'no-DAC' form (modified GRF 1-29) and a long-acting 'DAC' form.